migraine, FDA and Axsome

US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion Complex (MoSEIC) rapid-absorption technology. It combines with rizatriptan, a 5-HT1B/1D agonist, which was previously sold by Merck as Maxalt before it went generic. Triptans are a first-line class of treatments for migraine.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Per the company, Symbravo, a novel,
Axsome Therapeutics’ Promising Market Potential Following FDA Approval of Symbravo for Acute Migraine
Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of
FDA approves Axsome's novel migraine treatment SYMBRAVO
This news article is based on a press release statement from Axsome Therapeutics (NASDAQ:AXSM). The company continues to focus on addressing critical gaps in CNS treatment and advancing patient outcomes with its portfolio of FDA-approved and late-stage development programs.
Symbravo Approved for Acute Treatment of Migraine With or Without Aura
The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.
Axsome Therapeutics announces FDA approval of Symbravo
Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in
Axsome’s Migraine Medicine Clears FDA Bar
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
Redemption complete for Axsome’s Symbravo in migraine
CNS-focused biopharma Axsome Therapeutics has won US Food and Drug Administration (FDA) approval for Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
MedPage Today1d
Acute Migraine Treatment Gets a New Drug
The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...
Medscape1d
FDA Clears NSAID/Triptan Combo for Migraine in Adults
The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...
Axsome Shares Up Post Market After Hitting Record High on FDA Approval
Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients ...
FDA Approves the First Non-Opioid Pain Medicine in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...